Early report from this trial showed that the overall response rate was 24% for DLBCL patients (n = 17) who were administered combination treatment with BTK inhibitor and ani-STAT3 oligonucleotide [117]. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.